The U.S. Health Resources and Services Administration (HRSA) has updated its cervical cancer screening recommendations, introducing the option of self-administered Human Papillomavirus (HPV) tests for women aged 30 to 65 with an average risk of cervical cancer. This significant change aims to expand access to screening by reducing common barriers such as scheduling difficulties, discomfort, and limited access to healthcare facilities.
While a recent national study indicates a majority of women still prefer in-clinic screening, findings also suggest self-sampling holds potential for addressing disparities and increasing screening rates, particularly among underserved populations.
Updated Screening Recommendations
For women aged 30 to 65 with an average risk of cervical cancer, the HRSA now recommends an HPV test every five years. This test, which identifies human papillomavirus—a primary cause of cervical cancer—can be performed either through a self-swab method or by a clinician.
While Pap smears remain available, they are no longer designated as the primary screening method for this age group. Alternative choices for women aged 30 to 65 include a combination of an HPV and Pap test every five years, or a Pap test alone every three years if HPV testing is not available.
For women aged 21 to 29, the recommendations remain unchanged, advocating for Pap tests every three years.
Screening Methodologies and Technology
Self-administered HPV tests typically involve inserting a plastic tube into the vagina and twisting a handle to collect cells for laboratory analysis. In contrast, Pap smears require a clinician to use a speculum to widen the vaginal canal and swab the cervix for cell collection.
Studies have indicated that self-swab HPV tests demonstrate similar accuracy to those administered by a clinician.
The Food and Drug Administration (FDA) has expanded approvals for self-collection methods. As of 2024, the FDA has approved two self-swab tests for clinical use. The Teal Wand, an at-home device facilitating self-collection, has been approved for use, typically after a telehealth consultation, with some insurance plans providing coverage for its approximate $250 out-of-pocket cost. The first at-home self-collection cervical cancer screening kit, requiring a prescription, received FDA approval in May 2025.
Insurance Coverage and Accessibility
Private health insurers are generally mandated to cover preventive services recommended by HRSA. Consequently, these insurers are required to integrate the new screening guidelines and cover associated follow-up testing, including self-collection options, by January 1, 2027.
This coverage includes diagnostic evaluations such as additional Pap tests, biopsies, and laboratory work, without cost-sharing for the patient. A separate HRSA guideline, effective January 1, also mandates insurance coverage for patient navigation services, which assist women with scheduling and follow-up care.
Federal health officials have stated that the new guidelines are projected to increase screening rates, especially for women in rural areas or those with limited access to health clinics or doctor’s offices. Officials also noted that some women may prefer the privacy or comfort offered by self-swab tests.
Public Preference Study Findings
A national study published in JAMA Network Open, utilizing data from the 2024 Health Information National Trends Survey (HINTS 7), examined women's preferences for cervical cancer screening methods among 2,300 eligible women aged 21 to 65.
The study found that 60.8% of women preferred in-clinic screening, while 20.4% preferred at-home self-sampling, and 18.8% were unsure.
Key findings from the study include:
- Marginalized women, individuals overdue for screening, and those who had experienced prejudice or discrimination in medical care were more inclined to prefer at-home self-sampling.
- Women with low income and those expressing distrust in the healthcare system were more likely to be unsure of their preference.
- Black women exhibited a lower preference for at-home self-sampling compared to White women.
- Common reasons cited for preferring at-home HPV tests included privacy (54.9%), time constraints (35.1%), avoiding embarrassment from clinical examinations (33.4%), and reducing transportation costs.
Experts involved in the study suggested that home-based self-sampling can address barriers to cervical cancer screening and reduce inequities.
Cervical Cancer Context and Trends
Cervical cancer is largely preventable, with HPV causing an estimated 95% to 99% of cases. The disease results in approximately 4,000 deaths annually in the U.S., with around 13,000 new cases diagnosed each year. Projections from the National Cancer Institute anticipate approximately 13,500 new cases and 4,500 deaths in 2025.
Over the last 50 years, cervical cancer screening has contributed to a more than 50% reduction in incidence and deaths in the U.S. Early detection is associated with five-year survival rates exceeding 90%.
Despite progress, significant gaps persist in screening coverage. Roughly half of all cervical cancer diagnoses occur in women who have not been screened or whose screening is not up-to-date. Approximately one in four women in the U.S. aged 21 to 65 are not current with their screening recommendations.
Screening rates in this demographic decreased from 47% in 2019 to 41% in 2023, following the pandemic. Annual incidence rates have shown an increase among women in their 30s and early 40s, with a 1.7% annual rise between 2012 and 2019 for those aged 30-44. Potential contributing factors include delayed screenings or decreased uptake of HPV vaccinations, which were approved in 2006 and can prevent over 90% of cervical cancers.
Approximately 20% of cervical cancer cases occur in women over 65, a demographic often no longer included in routine screening protocols.
A positive HPV result indicates the need for further testing and does not constitute a cancer diagnosis.
Organizational Endorsements
The American Cancer Society (ACS) updated its recommendations in December, endorsing self-swab HPV tests every three years for women aged 25 to 65, while prioritizing clinician-administered HPV tests every five years. The U.S. Preventive Services Task Force (USPSTF) (2018) and the ACS (2020) have previously endorsed HPV testing of clinician-collected samples as a preferred screening method. The USPSTF has not yet officially endorsed self-sampling in its guidelines.
A Cervical Cancer Summit for patients, survivors, caregivers, and advocates is scheduled to take place in Washington D.C. at the end of January.